BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2026)
BioXcel Therapeutics (BTAI) recorded quarterly Gross Margin of 37.38% in Q1 2026, down 142.72% quarter-over-quarter from 87.5% in Q4 2025, and down 12905.0% on a YoY basis from N/an in Q1 2025.
BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2026) Analysis & Trends
BioXcel Therapeutics' Gross Margin history runs 5 years deep, the most recent figure standing at 37.38% for Q1 2026.
- In Q1 2026, Gross Margin fell 12905.0% year-over-year to 37.38%; the TTM figure through Mar 2026 stood at 36.32% (up 4853.0% YoY), while the FY2025 annual figure was 74.45%, up 6903.0% from the prior year.
- Gross Margin was 37.38% for Q1 2026 at BioXcel Therapeutics, down from 87.5% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 96.22% in Q4 2022 to a low of 446.73% in Q3 2024.
- Historically, Gross Margin has averaged 5.74% across 5 years, with a median of 87.5% in 2025.
- The sharpest annual moves came in 2024 and 2025: Gross Margin tumbled 39658 bps in 2024, then soared 53550 bps in 2025.
- A 5-year view of Gross Margin shows it stood at 96.22% in 2022, then sank by 193 bps to 89.89% in 2023, then tumbled by 42 bps to 127.32% in 2024, then soared by 169 bps to 87.5% in 2025, then plunged by 143 bps to 37.38% in 2026.
- The last three Gross Margin figures came in at 37.38% (Q1 2026), 87.5% (Q4 2025), and 88.78% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 49.52% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 71.66% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 82.93% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | 49.50% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 98.31% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 57.26% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -293.83% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 65.25% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 61.20% |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | -37.38% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -37.38% |
| Dec 31, 2025 | 87.50% |
| Sep 30, 2025 | 88.78% |
| Jun 30, 2025 | 10.83% |
| Mar 31, 2025 | 91.67% |
| Dec 31, 2024 | -127.32% |
| Sep 30, 2024 | -446.73% |
| Jun 30, 2024 | 94.38% |
| Mar 31, 2024 | 86.25% |
| Dec 31, 2023 | -89.89% |
| Sep 30, 2023 | -50.15% |
| Jun 30, 2023 | 94.31% |
| Mar 31, 2023 | 95.63% |
| Dec 31, 2022 | 96.22% |
| Sep 30, 2022 | 91.97% |